Welcome to our dedicated page for Verrica Pharmaceuticals SEC filings (Ticker: VRCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Verrica Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Verrica Pharmaceuticals's regulatory disclosures and financial reporting.
Verrica Pharmaceuticals Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 439,657 shares, representing 4.99% of the outstanding common stock.
The filing states the reported shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital exercises shared voting and dispositive power; the Master Fund disclaims beneficial ownership by virtue of its Investment Management Agreement. The joint filing is signed by Steven Boyd on 02/17/2026.
BKB Growth Investments, LLC reported its beneficial ownership of derivative securities of Verrica Pharmaceuticals Inc. through an amended ownership statement. The filing lists Series B Warrants, immediately exercisable, for 224,719 shares of Verrica common stock at an exercise price of $13.35 per share, expiring on 11/22/2029.
The warrants include a cap that prevents exercises that would push BKB Growth’s beneficial ownership above 19.99% of Verrica’s outstanding common stock after the exercise. The amendment explains that the original exercise price did not reflect Verrica’s 1-for-10 reverse stock split that took effect on July 24, 2025.
Affinity Asset Advisors, LLC and Michael Cho have filed an amended Schedule 13G reporting a passive ownership stake in Verrica Pharmaceuticals Inc. They report beneficial ownership of 884,172 shares of Verrica common stock, including 176,834 shares issuable upon exercise of warrants, representing approximately 5.5% of the company’s common stock.
The securities are held directly by Affinity Healthcare Fund, LP, for which Affinity Asset Advisors acts as investment manager. The reporting persons state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Verrica.
BKB Growth Investments, LLC filed an initial ownership report showing a significant stake in Verrica Pharmaceuticals Inc.. As of 11/25/2025, the entity beneficially owns 3,348,372 shares of Verrica common stock directly.
BKB Growth Investments, LLC also holds Series B warrants for 224,719 shares at an exercise price of $1.335 per share, expiring on 11/22/2029, and Series C warrants for 687,690 shares at $6.315 per share, expiring on 11/25/2030. The warrants are immediately exercisable but include a 19.99% beneficial ownership cap, limiting exercise if it would push the holder above that ownership level.
Verrica Pharmaceuticals Inc. is registering up to 14,756,230 shares of common stock for resale by existing stockholders under a shelf registration statement.
The Resale Shares consist of 6,499,826 already issued shares, up to 5,305,164 shares issuable upon exercise of pre-funded warrants, and up to 2,951,240 shares issuable upon exercise of common warrants that were sold in a November 2025 private placement.
Verrica will not receive proceeds from stockholder resales, but would receive cash if the warrants are exercised at $0.0001 per pre-funded warrant share and $6.315 per common warrant share. The company focuses on dermatology therapeutics, including its FDA-approved YCANTH (VP-102) for molluscum contagiosum, and its auditors have previously noted substantial doubt about its ability to continue as a going concern.
Verrica Pharmaceuticals Inc. (VRCA) reported an insider purchase by its Chief Medical Officer. On 11/25/2025, the CMO acquired 2,357 shares of common stock in an open market purchase at a price of $4.2425 per share, and now directly owns 2,357 common shares.
The filing also reports a derivative transaction involving a Series C warrant with an exercise price of $6.315. The warrant covers 589 shares of common stock, is immediately exercisable, and expires on 11/25/2030. The securities were purchased as part of 2,357 investment units, each consisting of one share of common stock and a Series C warrant for one fourth of a share. The warrant includes a 9.99% beneficial ownership limitation, preventing exercises that would push the holder above that ownership level.
Verrica Pharmaceuticals Inc. (VRCA) reported an insider purchase by its Interim CFO. On 11/25/2025, the executive bought 3,536 shares of common stock at $4.2425 per share, bringing their directly held common stock to 8,962 shares after the transaction.
The filing also reports acquisition of 884 Series C warrants with an exercise price of $6.315 per share, exercisable immediately until 11/25/2030, each warrant linked to common stock. All security amounts reflect a 1-for-10 reverse stock split effective July 24, 2025. The Series C warrants include a 9.99% beneficial ownership cap, limiting how many shares can be obtained through exercise relative to the company’s outstanding common stock.
Verrica Pharmaceuticals Inc. (VRCA) disclosed that its Chief Operating Officer filed a Form 4 reporting the purchase of 10,000 shares of common stock on 11/25/2025 at $4.2425 per share through investment units.
Each unit also included a Series C warrant, giving the right to buy one fourth of a share, resulting in warrants exercisable for 2,500 shares of common stock at an exercise price of $6.315, expiring on 11/25/2030. Following the transaction, the officer beneficially owned 21,000 shares of common stock and 2,500 Series C warrants. The warrants are immediately exercisable but contain a 9.99% beneficial ownership limitation, preventing exercises that would push the holder’s ownership above that level. The numbers reflect a 1-for-10 reverse stock split effective July 24, 2025.
Verrica Pharmaceuticals Inc. (VRCA) CEO, President and director reported a personal purchase of 94,311 investment units on 11/25/2025. Each unit includes one share of common stock and a Series C warrant to buy one fourth of a share, at a unit price of $4.2425.
The filing shows direct beneficial ownership of 182,593 common shares after the transaction, adjusted for a 1-for-10 reverse stock split effective July 24, 2025. The related Series C warrants cover 23,577 underlying common shares at an exercise price of $6.315 and are immediately exercisable, subject to a 9.99% beneficial ownership cap. Small additional holdings are reported indirectly through a child and family trusts.
Verrica Pharmaceuticals Inc. (VRCA) director and 10% owner Paul B. Manning reported large purchases of common stock and warrants. On 11/25/2025, he bought 1,375,380 investment units at $4.2425 per unit directly and 2,750,762 units indirectly through BKB Growth Investments, LLC. Each unit consists of one share of common stock and a Series C warrant to buy one fourth of a share at an exercise price of $6.315 per share, exercisable until 11/25/2030.
After these transactions, he beneficially owns millions of shares through direct holdings, BKB, family trusts and an investment entity, with some positions reported as disclaimed beneficial ownership. The Series C warrants are immediately exercisable but include a 49.99% beneficial ownership limitation, meaning they cannot be exercised to push his ownership above 49.99% of Verrica’s outstanding common stock after exercise. The reported share counts have been adjusted for Verrica’s 1-for-10 reverse stock split effective July 24, 2025.